About Lab21
Lab21 is a Healthcare company based in Cambridge (United Kingdom) founded in 2005 by Graham Mullis, and was acquired by Novacyt in May 2014. Personalised diagnostic testing for diseases and predisposition is specialised in. Lab21 has raised $837.8 thousand across 1 funding round from investors including Trinity Biotech and Novacyt. Lab21 has completed 1 acquisition, including Selah Technologies. Its focus areas include Diversified Diagnostics. Its legal entity is THE LAB21 LTD.
Company details
Lab21 was founded in 2005 in Cambridge, United Kingdom, within the personalised medicine diagnostics sector. Molecular testing services for cancer and virology diagnosis, along with treatment optimisation, are offered to patients. Proprietary antibodies and antigens for infectious diseases such as syphilis, CMV, TB, and malaria are manufactured. These products are distributed globally to blood banking and diagnostic markets.
- Total Equity Funding$837.8K (USD)
in 1 rounds
- Latest Funding Round$837.8K (USD), Seed
Oct 2010
- InvestorsTrinity Biotech
& 1 more
- Investments & Acquisitions
- Acquired by
Funding Insights of Lab21
Lab21 has successfully raised a total of $837.8K through 1 strategic funding round. The most recent funding activity was a Seed round of $837.8 thousand completed in October 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $837,800
- Total Rounds 1
- Last Round Seed — $837,800
- First Round $837,800
(Oct 2010)
All 1 funding rounds of Lab21 with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2010 | $837,800 | Seed | – | – | – |
2 investors in total: 2 institutional.
Investors in Lab21
Lab21 has secured backing from 2 investors. Prominent investors backing the company include Trinity Biotech and Novacyt.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Provider of In vitro diagnostic kits for clinical labs | 1992 | trinitybiotech.com | Bray, Ireland | |
Developer of cytology instruments and consumables for oncology and infectious disease | 2005 | novacyt.com | Velizy Villacoublay, France |
Investor details for Lab21
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Lab21
1 people are tracked at Lab21 (1 in leadership).
| Name | Role | Group |
|---|---|---|
Graham Mullis | Co-Founder | Leadership |
Complete people profiles for Lab21
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Lab21
Lab21 has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Selah Technologies.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Nano-enabled advanced materials are manufactured using proprietary nanotechnology products. | selahtechnologies.com | Greenville, United States | 2006 | Jun 2009 | •••• |
Complete acquisition details for Lab21
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Lab21
5 dated milestones of Lab21 across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Lab21 is founded.
- Acquisition Acquires Selah Technologies.
- Funding First funding round of $838K.
- Exit Acquired by Trinity Biotech.
- Exit Acquired by Novacyt.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Lab21
Complete news archive for Lab21
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lab21
Lab21 was founded in 2005 and raised its 1st funding round 5 years after it was founded.
Lab21 is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Lab21 is a funded company, having raised a total of $837.8K across 1 funding round to date. The company's 1st funding round was a Seed of $837.8K, raised on Oct 2010.
Lab21 was founded in 2005 in Cambridge, United Kingdom, within the personalised medicine diagnostics sector. Molecular testing services for cancer and virology diagnosis, along with treatment optimisation, are offered to patients. Proprietary antibodies and antigens for infectious diseases such as syphilis, CMV, TB, and malaria are manufactured. These products are distributed globally to blood banking and diagnostic markets.
Lab21 has made 1 acquisition, including Selah Technologies.
Lab21 has 2 investors. Key investors include Trinity Biotech, and Novacyt.
Lab21 operates through The Lab21 Ltd.
Yes. Lab21 was acquired by Novacyt in May 2014.